KarXT

KarXT is an investigational oral dual-drug fixed-dose combination of xanomeline and trospium which is currently being evaluated in a phase 3 clinical trial for the treatment of patients suffering from the symptoms of schizophrenia (see clinicaltrials.gov). Xanomeline is a functionally preferring muscarinic M4 and M1 receptor agonist that readily passes into the central nervous system (CNS) to stimulate these muscarinic receptor subtypes in key areas of the brain. Trospium is a non-selective muscarinic antagonist that does not cross into the CNS and reduces peripheral cholinergic side effects associated with xanomeline. rdf:langString